2023 World Baseball Classic Begins, Taiwan Excellence Supports
8.3.2023 11:10:00 EET | Business Wire | Press release
The World Baseball Classic (WBC) is returning to Taiwan, after a ten-year hiatus, for the qualifying rounds. The tournament will feature teams from Taiwan, the Netherlands, Cuba, Italy, and Panama, who will showcase their skills starting on March 8th. As the host country for the A-group preliminaries, Taiwan extends a warm welcome to the players through enthusiastic fans, fascinating cuisine, and the opportunity to experience the latest Taiwan Excellence awarded technology and lifestyle products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230311005004/en/
The WBC was postponed for two years due to the impact of COVID-19. With hygiene and safety being top priorities, Major League Baseball (MLB) has adopted stringent standards for the event. The Taiwanese organizers have prepared the world's first indoor wireless rapid antibacterial machine, the AQUECARE T1 Plus sanitizer. This innovative solution has received the Taiwan Excellence Award and will play a vital role in maintaining environmental hygiene throughout the tournament.
Because long-haul flights can cause fatigue among players, posing them a significant challenge, the organizers have provided the world's first AURAI intelligent eye massager in order to facilitate more rapid recovery. This device helps to alleviate eye fatigue, improves sleep quality, and will recharge energy levels for the players. They will also be able to use AROMASE all-in-one purifying gel which contains three different types of herbal extracts. This gel is effective in purifying the body and mind after each training session and competition. Furthermore, we prioritize environmental sustainability, and have prepared O’right toothpaste, a revolutionary toothpaste made from sustainable tree powder as a grinding agent. This toothpaste is certified by USDA Biobased.
Taiwan is well-known as a technology island, and its consumer electronics and ICT products have gained recognition from consumers worldwide. So, the organizers are providing the players with another Taiwan Excellence awarded product, the PX 4K HDR Wireless Presentation Receiver. This product supports 4K HDR wireless transmission and provides a convenient 4K wireless projection function from mobile phones and laptops to televisions, enabling players to relax and enjoy different forms of entertainment when away from the intensity of competition.
As a souvenir for players from around the world, the Qubii auto-backup device has been chosen. This is a hand-sized device that automatically backs up photos, videos, contacts, and other content while your phone is charging. This device allows players to easily back up precious game data and memories when they run out of phone storage.
Taiwan is making every effort to provide a comfortable and safe environment with the very best professional equipment, in the hopes that the teams will enjoy their stay in Taiwan and maximize their performance in the WBC. Taiwan Excellence, a globally recognized symbol of product quality and innovative design, plays an important role in this commitment. Taiwan Excellence will continue to discover and introduce more high-quality Taiwanese products, featuring innovative breakthroughs to the world, enriching the lives of people everywhere.
For more information, please visit our website https://www.taiwanexcellence.org/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230311005004/en/
Contact information
Brain Lee, TAITRA
brianlee@taitra.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
